PMC10051040_01
Baseline versus 2-month scan after 1 dose of AdAPT-001 versus 4-month scan on pembrolizumab versus month 7 on pembrolizumab (progressive disease). From left to right: baseline month 2 to one dose of AdAPT-001. From left to right: month 4 on pembrolizumab to month 7 on pembrolizumab (progressive disease).
cro529503_f01.jpg
PMC10051040_01_cro529503_f01.jpg
F1
AdAPT-001 and subsequent immunotherapy (Keytruda), is shown in Figure 1. A timeline is shown in Figure 2.
Timeline.
cro529503_f02.jpg
PMC10051040_01_cro529503_f02.jpg
F2
AdAPT-001 and subsequent immunotherapy (Keytruda), is shown in Figure 1. A timeline is shown in Figure 2.